Sinovac Biotech Co Ltd 29 Nov- 1Dec 2010 GENEVA
Sinovac Biotech Co Ltd (Nasdaq GM:SVA) Changping, Beijing Tangshan Yian Beijing Headquarters Sinovac Dalian Beijing Tangshan, Hebei Dalian, Liaoning Beijing Headquarters: Healive / Bilive annual capacity - 20million doses; Flu: 8million doses Changping: Plan to establish a new production line for EV71 a new filling packaging line in compliance with WHO stards Sinovac Dalian: Plan to establish production plants for live attenuated vaccine human rabies vaccine in Dalian Tangshan Yian: Plan to establish a production plant for animal rabies vaccine 2
Products R & D Sinovac is a fully integrated, profitable China-based biopharmaceutical company that focuses on researching, developing, manufacturing commercializing vaccine products for infectious diseases Key marketed products: Healive: leading inactivated hepatitis A vaccine in China Bilive: first combined inactivated hepatitis A B vaccine developed in China Anflu: split influenza vaccine Panflu: only approved H5N1 vaccine in China Panflu.1: first vaccine approved for H1N1 globally Rabies vaccine for animal Key pipeline cidates: Pneumococcal Conjugate Vaccine, EV71 (H, Foot & Mouth Disease), Rota Virus Vaccine, Japanese Encephalitis, Human Rabies vaccine, Hib Epidemic Meningitis, Chickenpox, Mumps & Rubella, Universal Flu vaccine. Founded in 2001 headquartered in Beijing 3 3
Compelling Top Bottom Line Growth Revenue Revenue Gross Profit Gross Profit Margin Margin 1 1 (U$m) (US$m) (US$m) Operating Operating Income Income Margin Margin Net Net Profit Profit Margin Margin Note:1 Gross profit margin is prior to deduction of depreciation of l use rights amortization of licenses permits 4 4
Commercial Performance Healive Healive (Hep (Hep A) A) Vaccine Vaccine 2009 2009 Healive Healive Market Market Share Share Thous Doses Chuangcun 16% Pukang 13% GSK 11% Sinovac 23% Chuangsheng 7% Berna 1% Kunming 29% Thous Doses 6,000 5,000 4,000 3,000 2,000 1,000 - Anflu Anflu (Seasonal (Seasonal Influenza) Influenza) Vaccine Vaccine 70 1,528 1,454 5,112 2006 2007 2008 2009 5 Ors* 7% Sanofi 15% 2009 2009 Anflu Anflu Market Market Share Share Hualan 13% Yalifeng 8% Shanghai 8% Sinovac 11% Changsheng 8% GSK 9% Tianyuan 11% Yanshen 10% Ors include: Novartis, Berna, Solvay, Tiantan, Changhun, Lanzhou
Attractive Healthcare Industry Trends In China Favorable Favorable Macro Macro Demographic Demographic Trends Trends Will Will Continue Continue to to Drive Drive China s China s Pharma Pharma Industry Industry Population in 2007 (million) 1,500 1,000 500 0 World s largest population... China India US Indonesia Brazil Pakistan Bangladeshi Nigeria Russia Japan Annual per capita disposable income of urban population (US$) increasing disposable income 2,500 2,000 1,500 1,000 500 0 1,241 increasing healthcare spending Source: World Bank, 2008 Source: China Statistical Yearbook 2008 Source: PRC National Bureau of Statistics 2,020 2003-2007 CAGR: 12.9% 2003 2007 Annual per capita expenditure on healthcare of urban population (US$) 120 100 80 60 40 20 0 70 102 2003-2007 CAGR: 10.1% 2003 2007 Chinese Chinese Government Government Has Has Announced Announced a a Healthcare Healthcare Reform Reform Plan Plan Valued Valued at at US$125 US$125 billion billion The goal is to establish a basic, universal healthcare framework by establishing: public health services system public medical insurance system public healthcare delivery system drug supply system This system focuses on preventing diseases is designed to provide free services such as immunizations, regular physical check-ups, prevention of infectious or chronic diseases or preventive public health services The government will establish facilities or install equipment to facilitate vaccination, which will continue to drive dem for vaccines Source: 2009 Healthcare Reform (April 6, 2009) 6 6
China s s Vaccine Market Is Poised for Strong Growth Increasing Government Spending on Exped Program of Immunization (EPI) Vaccine coverage exped to preventing 15 diseases from 7. Strong Government Support of Disease Prevention ~ $800mil spending on vaccine purchase in 2009, including purchase of H1N1 vaccine. 40+ manufacturers RMB5.2bn (US$762m) market size Public market: RMB2.2bn (US$322m) Private market RMB3.0bn (US$440m) National Immunization Plan covers 15 types of diseases Industry Consolidation has started Recent Outbreaks of Newly Emerging Pemic Diseases SARS, H5N1, H1N1 EV71 Industry Capacity Constraints Lead to Furr Consolidation however, spending on pediatric vaccines is still significantly lower than developed countries Source: Biopharmaceutical Industry Summit 2009 Bacterin Day (Dec 10, 2009) 7 7
Growth Strategy 1 Develop Develop more more vaccines vaccines (available (available new) new) that that address address unmet unmet medical medical needs needs - - Against Against newly newly emerged emerged diseases diseases - - To To improve improve quality quality profile profile of of vaccines vaccines available available in in market market 2 Exp Exp our our capacity capacity to to meet meet needs needs of of growing growing Chinese Chinese market market or or geographic geographic markets markets 3 Keep Keep improving improving quality quality system system meet meet international international stards stards 4 imaximize imaximize sales sales of of our our products products within within Chinese Chinese market market exp exp overseas overseas markets markets 5 Seek Seek international international collaboration collaboration on on R&D, R&D, industrialization, industrialization, commercialization commercialization 8 8
Experienced Committed Management Team 9
Regulatory Timeline Underst Chinese SFDA requirement of licensing vaccine products Proven Capabilities To register products with SFDA effectively: Underst regulation Well prepared documentation Smooth communication with experts officials Vaccine Highlights Lab-> Mrk 1993 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Healive 1 st inactivated hepatitis A vaccine developed & marketed in China Bilive 1 st combined inactivated hepatitis A B vaccine developed marketed in China Anflu With no preservatives 8yrs 7yrs 7yrs SARS 2 1 st to complete Phase I clinical trial Panflu 1 st only approved vaccine available in China against H5N1 Panflu.1 World s 1 st approved H1N1 vaccine 5yrs 87 days Development stage Commercial launch Source: Company filings, NICPBP Notes: 1 Based on NICPBP s lot release records volume based market share 2 Phase I clinical trial was completed in December 2004. As SARS epidemic has subsided, Company currently is not proceeding with furr clinical trials. However, should anor outbreak occur in future, Company believes it can rapidly initiate Phase II III trials. 10 10
Sales, Marketing Distribution We sell products directly to CDCs which enables us to better control supply chain gain deeper understing of end market Network coverage across China (except Tibet) ~71% city level CDCs ~44% of county level CDCs Expertise not only on pediatric market, but also adult market Maintaining leading position not only in top tier cities but second tier cities 11
Government Support Introduced inactivated Hep A Vaccine to President Hu Jingtao Introduced development of Pemic Influenza (H5N1) Vaccine to Premier Wen Jiabao Introduced development of H1N1 vaccine to Vice President Xi Jinping Introduced R&D preparation of H1N1 vaccine to Vice Premier Li Keqiang An established synergy: Creation of interactive network with both central, Beijing or provincial government organizations. Participation on 13 national 16 Beijing research programs since 2001 Benefit from favourable policies on HR, investment, taxation, government procurement infrastructure dedicated to local biopharmaceutical leaders Sinovac is is willing willing ready ready to to share share it it with with our our future future partners 12
Thanks for your great work on vaccines. We can partner to make sure even more children get m! --Bill Gates
Thanks 14
Changping Vaccine Production Center Address: No. 15, Zhi Tong Road, Changping Science Park, Changping District, Beijing L Area: 29,000 square meters Building Area:32,000 square meters 15
Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian) Address: No. 36, 2 nd Road, DD Port, Economic Technical Development Zone, Dalian 116620, China L Area: 95,000 square meters Building Area:20,000 square meters Submitted Mumps vaccine clinical trial application to SFDA Upgrading production R&D projects: rabies, chickenpox, rotavirus rubella Seeking international collaboration opportunities for MMR vaccine
Tangshan Yi an Animal Vaccine Production Center GMP production line construction on animal rabies vaccine Address: No. 120, Huoju Road, Hi-tech development Area, Tangshan City L Area: 13,500 square meters Building Area: 3,780 square meters 17
Office Area: 16,700 square meters Production Area:32,200 square meters
Our Mission Sinovac is open ready to cooperate with any international partner to do Biotechnology transfer. 19